Achievement of pre-clinical milestone triggers $4M payment from GSK to Epizyme Epizyme.

Related StoriesCrucial transformation in single DNA base predisposes children to intense type of cancerNew antenna-like device makes breast cancer medical procedures less difficult for surgeonsFDA grants accelerated acceptance for Tagrisso to take care of patients with advanced NSCLCRobert Copeland, Ph.D., CSO and EVP of Epizyme, stated: ‘The rapid progress we have manufactured in our alliance with GSK provides further validation of Epizyme’s ability to discover little molecule histone methyltransferase inhibitors as individualized therapeutics for genetically-described cancer patients.’ The GSK alliance leverages Epizyme’s exclusive HMT discovery platform, including its proprietary biology, biochemistry, chemical library, experience, and intellectual home, to discover and develop HMT therapeutics against the set of targets included in the collaboration.False excellent results of sigmoidoscopy, without neoplasia recognized at subsequent diagnostic assessment, were observed among 20 percent of men and 13 percent of women.27 A few of the false positive sigmoidoscopic examinations might have been due to false negative results of colonoscopy. Deaths from other causes, excluding prostate, lung, colorectal, and ovarian cancers, totaled 9138 in the intervention group and 9286 in the usual-treatment group . Endoscopic Contamination The estimated rate of endoscopic contamination in the usual-care group during the screening phase was 25.8 percent for flexible sigmoidoscopy, 34.4 percent for colonoscopy, and 46.5 percent for either flexible sigmoidoscopy or colonoscopy.